In the SLATE phase I/II, patients with pretreated non-small cell lung cancer, microsatellite stable colorectal cancer, pancreatic ductal adenocarcinoma, ovarian cancer, and ampullary adenocarcinoma with KRAS mutations were administered the off-the-shelf heterologous vaccines (encoding various KRAS mutations). This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.